Open Access Open Access  Restricted Access Subscription or Fee Access

Advancements in Medicinal Approaches for Vitiligo Management: From Ancient Remedies to Modern Therapies

Sandip Gahininath Badadhe, Preeti Kulkarni, Ganesh S Gangarde, Tejas S Gangarde

Abstract


Vitiligo, a skin disorder marked by patchy loss of color, poses substantial challenges to physical and mental well-being. Affecting about 1% of the global population with varying prevalence regionally, this condition demands a nuanced understanding for effective treatment. This article delves into vitiligo’s historical roots, tracing references from ancient medical literature to contemporary medicinal approaches. Exploration begins with the classification, symptoms, and diagnostic methods of vitiligo. Pathogenesis hypotheses, including autoimmune and genetic factors, are examined. The study emphasizes the multifaceted impact on patients, considering both physical and psychological aspects. A comprehensive overview of vitiligo management is presented, covering various treatment modalities. Non-surgical options like topical therapy and phototherapy are discussed in detail, highlighting their efficacy and limitations. Surgical interventions, such as punch grafting and cultured melanocyte grafting, are explored as alternative strategies. Throughout the discussion, the evolution of therapeutic strategies is emphasized. From ancient remedies to contemporary advancements, the article underscores the dynamic nature of vitiligo treatment. Understanding historical contexts and embracing innovative approaches enhance healthcare practitioners & ability to address diverse needs, promoting holistic well- being. In conclusion, vitiligo’s complex nature requires a holistic approach to treatment, acknowledging historical perspectives while integrating modern advancements. This nuanced understanding ensures that healthcare strategies evolve to meet the diverse needs of individuals with vitiligo, ultimately improving their overall quality of life.

Keywords


Vitiligo, Melanocytes, Skin disorder, Repigmentation Treatment, skin examination.

Full Text:

PDF

References


Suryawanshi, M. (2018). Introduction to vitiligo and its treatment: a review. International Journal of Pharmaceutical Research and Medicinal Plants, 1(2), 72-75.

Ghafourian, E., Ghafourian, S., Sadeghifard, N., Mohebi, R., Shokoohini, Y., Nezamoleslami, S., & Hamat, R.A. (2014). Vitiligo: symptoms, pathogenesis and treatment. International Journal of Immunopathology and Pharmacology, 27(4), 485-489.

Gianfaldoni, S., Wollina, U., Tchernev, G., Lotti, J., França, K., & Lotti, T. (2018). Vitiligo in children: a review of conventional treatments. Open Access Macedonian Journal of Medical Sciences, 6(1), 213.

Panda, A.K. (2005). The medico-historical perspective of vitiligo. Bulletin of the Indian Institute of History of Medicine, 25, 41-46.

Jaiswal, K.P., Sarsavan, A., Kumar, C.R., Ali, S.A., & Tembre, M.K. (2014). The etiological features and treatment of vitiligo: A pilot study prospective to Indian scenario. International Journal of Scientific Research in Biological Sciences, 1, 10-17.

Alkhateeb, A., Fain, P.R., Thody, A., Bennett, D.C., & Spritz, R.A. (2003). Epidemiology of vitiligo and associated autoimmune diseases in Caucasian probands and their families. Pigment Cell Research, 16(3), 208-214.

Kemp, E.H., Waterman, E.A., Hawes, B.E., O’Neill, K., Gottumukkala, R.V., Gawkrodger, D.J., Weetman, A.P., & Watson, P.F. (2002). The melanin-concentrating hormone receptor 1, a novel target of autoantibody responses in vitiligo. The Journal of Clinical Investigation, 109(7), 923-930.

Ralf Paus, L., Schallreuter, K.U., Bahadoran, P., Picardo, M., Slominski, A., Elassiuty, Y.E., Kemp, E.H., Giachino, C., Liu, J.B., Luiten, R.M., & Lambe, T. (2008). Vitiligo pathogenesis: autoimmune disease, genetic defect, excessive reactive oxygen species, calcium imbalance, or what else? Experimental Dermatology, 17(2), 139-140. 9]Laberge, G., Mailloux, C.M., Gowan, K., Holland, P., Bennett, D.C., Fain, P.R., & Spritz, R.A. (2005). Early disease onset and increased risk of other autoimmune diseases in familial generalized vitiligo. Pigment Cell Research, 18(4), 300-305.

Gauthier, Y., Cario-Andre, M., Lepreux, S., Pain, C., & Taieb, A. (2003). Melanocyte detachment after skin friction in non-lesional skin of patients with generalized vitiligo. British Journal of Dermatology, 148(1), 95-101.

Boissy, R.E. and Manga, P. (2004). On the etiology of contact/occupational vitiligo. Pigment Cell Research, 17(3), 208-214. 12]Baldini, E., Odorisio, T., Sorrenti, S., Catania, A., Tartaglia, F., Carbotta, G., Pironi, D., Rendina, R., D’Armiento, E., Persechino, S., & Ulisse, S. (2017). Vitiligo and autoimmune thyroid disorders. Frontiers in Endocrinology, 8, 290.

Tahir, M.A., Pramod, K., Ansari, S.H., & Ali, J. (2010). Current remedies for vitiligo. Autoimmunity Reviews, 9(7), 516-520.

Kwon HB, Choi Y, Kim HJ, Lee AY. (2013). The therapeutic effects of a topical tretinoin and corticosteroid combination for vitiligo: a placebo-controlled, paired-comparison, left-right study. Drugs in Dermatology, 12(4), e63–e67.

Yamanaka, K.I., Kakeda, M., Kitagawa, H., Tsuda, K., Akeda, T., Kurokawa, I., Gabazza, E.C., Kupper, T.S., & Mizutani, H. (2010). 1, 24‐Dihydroxyvitamin D3 (tacalcitol) prevents skin T‐cell infiltration. British Journal of Dermatology, 162(6), 1206-1215.

AlGhamdi, K., Kumar, A., & Moussa, N. (2013). The role of vitamin D in melanogenesis with an emphasis on vitiligo. Indian Journal of Dermatology, Venereology and Leprology, 79, 750.

Khan, N., Ali, S.A., & Parveen, N. (2017). The intricacies of vitiligo with reference to recent updates of treatment modalities. Ejpmr, 5(02), 187-196.

Falabella, R. and Barona, M.I. (2009). Update on skin repigmentation therapies in vitiligo. Pigment Cell & Melanoma Research, 22(1), 42-65.

Mehdianrad, M. (2009). The efficacy of topical immunomodulators in treating vitiligo. https://commons.pacificu.edu/work/sc/1df6607a-8aa9-431e-80ff-c0c531c0ee17

Du, J., Wang, X.Y., Ding, X.L., Xu, Q.X., Chen, Z., Chang, J.M., & Zhang, J.Z. (2013). Long-term efficacy and safety of tacrolimus ointment in the treatment of vitiligo. The Journal of Dermatology, 40(11), 935-937.

Falabella, R. and Barona, M.I. (2009). Update on skin repigmentation therapies in vitiligo. Pigment Cell & Melanoma Research, 22(1), 42-65.

Sun, Y., Wu, Y., Xiao, B., Li, L., Li, L., Chen, H.D., & Gao, X.H. (2015). Treatment of 308- nm excimer laser on vitiligo: a systemic review of randomized controlled trials. Journal of Dermatological Treatment, 26(4), 347-353.

Vussuki, E., Ziv, M., Rosenman, D., & David, M. (2006). Long-term effects of PUVA therapy on Israeli patients with vitiligo. Harefuah, 145(7), 483-5.

Rordam, O.M., Lenouvel, E.W., & Maalo, M. (2012). Successful treatment of extensive vitiligo with monobenzone. The Journal of Clinical and Aesthetic Dermatology, 5(12), 36.

Sharquie, K.E. (2014). Hayder Al-Hamamy H, Noaimi AA, Al-Marsomy MA, Salman HA. Direct electrical current is a new therapeutic option for vitiligo. American Journal of Dermatology and Venereology, 3(1), 9-12.

Parsad, D., & Gupta, S. (2008). Standard guidelines of care for vitiligo surgery. Indian Journal of Dermatology, Venereology and Leprology, 74, 37.

Lahiri, K., Malakar, S., Sarma, N., & Banerjee, U. (2006). Repigmentation of vitiligo with punch grafting and narrow-band UV-B (311 nm)–a prospective study. International Journal of Dermatology, 45(6), 649-655.

Linthorst Homan, M.W., Spuls, P.I., Nieuweboer-Krobotova, L., De Korte, J., Sprangers, M.A.G., Bos, J.D., Wolkerstorfer, A., & van der Veen, J.P.W. (2012). A randomized comparison of excimer laser versus narrow-band ultraviolet B phototherapy after punch grafting in stable vitiligo patients. Journal of the European Academy of Dermatology and Venereology, 26(6), 690-695.

Agrawal, K., & Agrawal, A. (1995). Vitiligo: repigmentation with dermabrasion and thin split-thickness skin graft. Dermatologic Surgery, 21(4), 295-300.

Lotti, T., Hercogova, J., & Fabrizi, G. (2015). Advances in the treatment options for vitiligo: activated low-dose cytokines-based therapy. Expert Opinion on Pharmacotherapy, 16(16), 2485-2496




DOI: https://doi.org/10.37591/(rrjops).v14i3.1361

Refbacks

  • There are currently no refbacks.


Copyright (c) 2023 Research and Reviews: A Journal of Pharmaceutical Science